Rigel Pharmaceuticals (RIGL) Other Non-Current Assets (2010 - 2026)

Rigel Pharmaceuticals' Other Non-Current Assets history runs 17 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• In Q1 2026, Other Non-Current Assets rose 55.47% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.4 million (up 55.47% YoY), while the FY2025 annual figure was $1.9 million, up 24.95% from the prior year.
• Other Non-Current Assets was $2.4 million for Q1 2026 at Rigel Pharmaceuticals, up from $1.9 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $5.0 million in Q3 2023 to a low of $403000.0 in Q2 2022.
• Historically, Other Non-Current Assets has averaged $2.2 million across 5 years, with a median of $1.5 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Other Non-Current Assets jumped 923.97% in 2023, then sank 75.49% in 2025.
• A 5-year view of Other Non-Current Assets shows it stood at $640000.0 in 2022, then surged by 377.34% to $3.1 million in 2023, then tumbled by 50.02% to $1.5 million in 2024, then rose by 24.95% to $1.9 million in 2025, then grew by 23.53% to $2.4 million in 2026.
• The last three Other Non-Current Assets figures came in at $2.4 million (Q1 2026), $1.9 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.